Tenaya Therapeutics

Name: Tenaya Therapeutics
Address: 171 Oyster Point Boulevard, Ste 500, South San Francisco, CA, 94080, US
Telephone: +16508256990

Call Directions Website Contact the business

We discover and develop genetic medicines to improve the lives of people with heart conditions. At Tenaya, we believe we can do better. audiences.

Heart conditions come in many forms, affecting individuals of all ages and backgrounds. Yet often, treatments have taken a one-size-fits-all approach, with a few commonly used medicines prescribed to manage symptoms. Tenaya is 100% committed to discovering and developing new medicines for heart conditions. We hope to not just alleviate symptoms, but to change the course of disease by targeting its underlying genetic causes. Founded by leading researchers specializing in genetic medicines, rare diseases and the biology of the heart, Tenaya built specialized capabilities to translate our scientific insights into new treatments. We are currently advancing a pipeline of investigational therapeutics with the potential to transform and extend the lives of patients. Tenaya was founded by leading cardiovascular scientists and we work to incorporate the patient community voice in everything we do. We formed a Patient Advisory Council (PAC) of community members with cardiomyopathies in 2022 so that we could learn directly from people with these conditions early and often. We meet with this group of ~12 individuals regularly to obtain input on study design, educational materials, and unmet needs of the patient community. This page is sponsored by Tenaya Therapeutics. Please note that certain content on our page is intended for U.S. Tenaya’s gene therapies are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other countries’ health authority or regulatory agency.

10/08/2026

Meet Dean. A surgeon, photographer, father and lifelong adventurer, Dean traveled to all seven continents and about 40 countries with his family. But after developing serious heart rhythm problems, his life changed dramatically.

Dean lives with arrhythmogenic cardiomyopathy (ACM) caused by a PLN mutation—a genetic change that also runs through his family. His experience has meant stepping away from the career and activities he loved, while watching other family members face their own risks from the same mutation.

Today, Dean has found a new sense of purpose: helping raise awareness of PLN-related heart disease and advocating for others living with it with the PLN Foundation.

Read Dean’s story and learn more about his family’s journey with PLN:
on our website Dean’s Story (link in Bio).

10/05/2026

Every family deserves answers, support, and a community that understands their journey. That's why we are proud to sponsor the 2026 FIA - Foundation for Inherited Arrhythmias Conference, November 13 - 15 in Houston. Learn more: fiacardiac.org

10/01/2026

stepped out for heart health! ❤️👟

On September 24, our team came together for the American Heart Association Heart Walk—supporting a cause that is closely connected to the work we do every day. It was a great opportunity to spend time together outside the office while showing our support for patients, families and everyone impacted by heart disease.

Thank you to everyone who walked with us and helped make the day a memorable one!

09/29/2026

Today is World Heart Day ❤️

This year’s theme, “Don’t Miss a Beat,” reminds us that in the rush of daily life, it’s easy to overlook the small moments that make a big impact: taking a walk, spending time with loved ones, or checking in on a friend.

At Tenaya, we’re committed to the mission of developing genetic medicines that target the root causes of rare heart diseases like hypertrophic cardiomyopathy ( ) and arrhythmogenic right ventricular cardiomyopathy ( ).

💬 How do you take care of your heart health each day?

09/24/2026

What do we mean when we talk about protein expression?

Protein expression is the process by which cells make protein from instructions in genetic information.

certain genetic mutations may result diseases like or because the body is missing a needed protein for the heart to work as it should.

The goal of is to deliver a working gene to allow the body to make the protein it may be lacking.

Read all about protein expression in our resource From Gene to Protein: A Closer Look at Gene Therapy for Heart Conditions: link in Bio.

09/21/2026

September is Inherited Arrhythmia Awareness Month, recognizing conditions that occur when the electrical system of the heart is not working properly, so that the heart beats with an abnormal rhythm.

ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy) causes 15%-25% of heart-related deaths in people under 35, and in 20% of cases sudden cardiac death is the first sign of disease. The exact prevalence of ARVC is unknown but is estimated to be between 1 in 5000 to as high as 1 in 1000 people.

Visit fiacardiac.org for more information.

09/18/2026

Safety is built into every stage of Tenaya’s approach to gene therapy—from the therapeutic gene and capsid design to dose selection, temporary immunosuppression, and close monitoring after an infusion.

Each element is carefully considered to help optimize both safety and potential benefit for participants. Our trials also include ongoing assessments and oversight by external experts across cardiology, hepatology, immunology, and AAV gene therapy.

This comprehensive approach reflects our commitment to advancing innovative treatments responsibly, with patient safety at the center.

09/15/2026

Our team recently gathered in Yosemite for a company retreat filled with time to connect, reflect and celebrate all that we’ve accomplished together.

From hiking Yosemite’s trails to s’mores, games and plenty of laughs, it was a memorable few days.

We’re grateful to everyone who has been part of Tenaya’s first decade and energized for our next chapter! 💙

09/14/2026

Today, we announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401, Tenaya’s gene therapy candidate for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Our CEO Faraz Ali noted:

"RMAT designation underscores the continued recognition by regulators of the seriousness of PKP2-associated ARVC and the potential of TN-401 gene therapy to change the course of disease by addressing its underlying cause. This designation is supported by the encouraging interim data generated to date from our RIDGE-1 trial, which demonstrated clinically meaningful reductions in daily rates of PVCs and NSVTs, as well as a favorable tolerability profile. Together with Fast Track and Orphan Drug designations, RMAT enhances our ability to engage with the FDA as we strive to advance TN-401 toward a pivotal trial in order to bring this potentially transformative treatment to patients as quickly as possible. We look forward to sharing additional data from RIDGE-1 in the fourth quarter and providing an update on our ongoing discussions with regulators regarding pivotal trial plans for TN-401."

Learn more at our website.

09/10/2026

Meet Gabe, an 11-year-old from Florida who was diagnosed with hypertrophic cardiomyopathy (HCM) at just 2 months old. ❤️

In recognition of Children’s Cardiomyopathy Awareness Month, Gabe and his family are bringing their community together for a 5K & Fun Run on September 19 in Okeechobee, Florida, benefiting Children's Cardiomyopathy Foundation .

We invite you to walk, run, and come together in support of children and families affected by cardiomyopathy. All ages and all paces are welcome!

Can’t make it to Okeechobee? There are other walks taking place across the country, as well as individual ways to participate and show your support from wherever you are.

Learn more and join the walk: https://www.childrenscardiomyopathy.org/unique/get-involved/attend-event-walk.html

Read Gabe’s story on our website (link in Bio)

Address

171 Oyster Point Boulevard, Ste 500
South San Francisco, CA
94080

Telephone

+16508256990

Website

https://www.tenayatherapeutics.com/patients, https://linktr.ee/tenayatherapeutics

Alerts

Be the first to know and let us send you an email when Tenaya Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Tenaya Therapeutics:

Want your business to be the top-listed business in South San Francisco?